# Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury

> **NCT00597818** · PHASE2 · COMPLETED · sponsor: **Sucampo Pharma Americas, LLC** · enrollment: 121 (actual)

## Conditions studied

- NSAID-induced Gastroduodenal Injury
- Ulcers
- Rheumatoid Arthritis
- Osteoarthritis

## Interventions

- **DRUG:** Cobiprostone
- **DRUG:** Placebo
- **DRUG:** Non-steroidal anti-inflammatory drug

## Key facts

- **NCT ID:** NCT00597818
- **Lead sponsor:** Sucampo Pharma Americas, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2009-04
- **Final completion:** 2009-05
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2019-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00597818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00597818, "Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00597818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*